Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

CertaraJune 9, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

CertaraJune 9, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

Publication

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

CertaraMay 21, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

CertaraMay 20, 2026

Webinar

Minimize risk when preparing for hepatic impairment studies

CertaraMay 12, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle PillsburyMay 8, 2026

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

CertaraMay 8, 2026

Blog

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

CertaraMay 8, 2026

Clinical Pharmacology

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Minimize risk when preparing for hepatic impairment studies

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

What We Learned at Phoenix UGM at Certainty 2026 About the Future of PK/PD

Newsletter sign up

Quick links

Solutions

Contact